中期肝细胞癌TACE联合索拉非尼治疗结果—SPACE研究课件.pptxVIP

中期肝细胞癌TACE 联合索拉非尼治疗结 果—SPACE 研究 读书汇报 Mu Luwen 2016-04-27 肿瘤防治中心 SUNYAT-SEN UNIVERSITYCANCER CENTER SYSUCC SINCE¹964 2 Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial Riccardo Lencioni², Josep M. Llovet³451, Guohong Han,Won Young Tak?, Jiamei Yang, Alfredo Guglielmi,Seung Woon Paikl, Maria Reig?, Do Young Kim, Gar-Yang Chau², Angelo Luca¹³,Luis Ruiz del Arbol4, Marie-Aude Leberre5,Woody Niu⁶, Kate Nicholson?, Gerold Meinhardt8, Jordi Bruix³ University of Miami Miller School of Medicine, Miami, Fl, USA;²pisa University School of Medicine, Pisa, Italy;³Barcelona Cfinic Liver Cancer (BCLC) Group, Liver Unit, Institut dnvestigacions Biomediques, August Pi i Sunyer (IDIBAPS), Hospital Clinic Barcelona, CIBERehd, Barcelona, Spain; 4Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York, NY, USA; institucio Catalana de Recerca i Estudis Avangats, Catalonia, Spain;6xijing Hospital, Fourth Military Medical University,Xian, China; 7kyungpook National University Hospital, Daegu, South Korea; sShanghai Easterm Hepatobiliary Surgery Hospital, Shanghai,China;9University ofVerona Medical School, Verona,ltaly; 1Osamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;Yonsei University College of Medicine, Seoul, South Korea; 12Taipei Veterans General Hospital,National Yang-Ming University, Taipei, Taiwan;13Mediterranean nstitute for Transplantation and Advanced Specialized Therapies, University ofPittsburgh Medical Center Italy, Palermo, Italy;Hospital Ramon y Cajal,University of Alcald, Madrid, Spain; 15Bayer HealthCare Pharmaceuticals, Loos, France; 16Bayer HealthCare Co, Ltd, Beijing, China; 1Bayer Plc, Newbury, UK; 18Bayer HealthCare Pharmaceuticals, Montville, N, USA Research Article CrossMark 3 · Asymptomatic · Non-invasive · Multinodular · Unresectable tumors ·Adequate preservation of liver function Intermediate stage (Barcelona clinic liver cancer stage